News
Interviews
Opinions
Columns

ESMO events

ESMO Targeted Anticancer Therapies Congress 2023

topics

Cancer Diagnostics Cancer Research Pathology/Molecular Biology Genetic and Genomic Testing Laboratory Diagnostics Clinical Research Practice tools and resources Translational Research Targeted Therapy Tumour Immunology Molecular Oncology

Date

Reset

Search results (7)

Cancer Diagnostics

6 Mar 2023

NGS – a weapon in molecular pathology?

Umberto Malapelle

Cancer Research

6 Mar 2023

New tools and methods are discussed for optimising investigation of precision therapeutics

Cancer Research

6 Mar 2023

Early phase cancer research – ready for a change?

Cancer Research

6 Mar 2023

Improving collaboration to expedite early-phase research in oncology

Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations

By Andres Cervantes

Cancer Research

7 Mar 2023

Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy

Targeted Therapy

7 Mar 2023

Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours

13 Feb 2023

ESMO Targeted and Anticancer Therapies Congress 2023 – See you in Paris

Watch video

Daily Reporter

Twitter
Facebook
Youtube
RSS
LinkedIn
Instagram

The ESMO Daily Reporter is the ESMO official newspaper covering science from Society's events, and providing news and views on the key topics in oncology.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano – CH

Home
Editorial Board
All News

Privacy Policy
ESMO Website

ESMO Targeted Anticancer Therapies Congress 2023

topics

Search results (7)

NGS – a weapon in molecular pathology?

New tools and methods are discussed for optimising investigation of precision therapeutics

Early phase cancer research – ready for a change?

Improving collaboration to expedite early-phase research in oncology

Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy

Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours

ESMO Targeted and Anticancer Therapies Congress 2023 – See you in Paris

New tools and methods are discussed for optimising investigation of precision therapeutics